Company intelligence / Profile preview

Hans Biomed

Ownership: Private
Employees: ~378
Development stage: Commercial

Overview

Hans Biomed has a broad commercial portfolio in biologics and medical devices for tissue engineering and aesthetic medicine. Its products are used globally for breast reconstruction/augmentation, facial lifting procedures with PDO threads, bone grafting materials for orthopedic/dental use, acellular dermal matrices for reconstructive surgery, hair transplantation devices, and scar management solutions. The company was the first in South Korea to establish a tissue bank and has been recognized as a "World Top-Class Product Company" by the Korean government.

Therapeutic areas: OtherDermatologyWomen's Health
Modalities: BiologicMedical deviceCell therapyTissue engineering product
Industry: Implantable Medical Devices

Drug pipeline

2 assets

BellaGel

Commercial

Indications: Breast augmentation

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Hans Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hans Biomed.

Explore the full profile